-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

Benzinga·04/01/2026 21:01:09
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the price target from $9 to $5.